The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Christopher Young: Welcome everyone and thank you for joining us. It's great to join you on my first earnings conference call as President and CEO of Vertex. Our financial results for the fourth ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Therefore, the risk of a downside surprise has increased. In light of this less compelling risk/reward profile, I am downgrading Vertex to Hold. Vertex Pharma: Q4 2025 Earnings Preview While headline ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...

Vertex has delivered earnings growth over the past decade thanks to its leadership in cystic fibrosis treatment. In recent years, the company has launched products in other treatment areas too. On top ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without regular ...

M.D. Ph.D., 50 Northern Ave, Boston, Massachusetts 02210, Chief Scientific Officer, Executive Vice President, Global Research Vertex Pharmaceuticals Incorporated; Senior Lecturer on Genetics and on ...

Abstract: Intelligent reflecting surface (IRS) is an enabling technology to engineer the radio signal propagation in wireless networks. By smartly tuning the signal reflection via a large number of ...